The past three months have seen significant changes in the analyst evaluations of Evolus (NASDAQ:EOLS), with four analysts providing updates on their outlooks for the company. These evaluations showcase a range of sentiments, from bullish to bearish, giving investors a better understanding of the potential risks and opportunities associated with Evolus.
The table below outlines the recent ratings from these analysts, providing insight into their evolving perceptions over the past 30 days and comparing them to the previous months. Overall, the breakdown of the ratings indicates a shift towards a more positive outlook for the company.
Ratings Breakdown:
Bullish: 3, Somewhat Bullish: 1, Indifferent: 0, Somewhat Bearish: 0, Bearish: 0
Rating Changes Over Time:
Last 30 days: 1 Bullish, 1 Somewhat Bullish, 0 Indifferent, 0 Somewhat Bearish, 0 Bearish
1M Ago: 0 Bullish, 0 Somewhat Bullish, 0 Indifferent, 0 Somewhat Bearish, 2 Bearish
2M Ago: 2 Bullish, 0 Somewhat Bullish, 0 Indifferent, 0 Somewhat Bearish, 0 Bearish
3M Ago: 0 Bullish, 0 Somewhat Bullish, 0 Indifferent, 0 Somewhat Bearish, 0 Bearish
The 12-month price targets from these analysts offer further insights into their perceptions of Evolus’s potential. The average price target of $22.75 represents a slight increase from the previous average of $21.75, showcasing a positive shift towards the company. The high estimate of $27.00 and the low estimate of $20.00 provide a range of possible outcomes, giving investors a better idea of the potential risks and rewards associated with Evolus.
Below, we break down recent analyst actions and their evaluation of Evolus, including any adjustments to their ratings and price targets.
Analyst Ratings and Price Targets:
Balaji Prasad - Barclays:
Action Taken: Raises Rating to Overweight
Current Price Target: $20.00
Prior Price Target: $16.00
Serge Belanger - Needham:
Action Taken: Maintains Buy Rating
Current Price Target: $22.00
Prior Price Target: $22.00
Serge Belanger - Needham:
Action Taken: Maintains Buy Rating
Current Price Target: $22.00
Prior Price Target: $22.00
Douglas Tsao - HC Wainwright & Co.:
Action Taken: Maintains Buy Rating
Current Price Target: $27.00
Prior Price Target: $27.00
Analyst actions and recommendations often reflect significant developments and market conditions. Changes in ratings, such as ‘Maintain’, ‘Raise’, or ‘Lower’, can offer valuable information to investors. These reactions provide a unique perspective on Evolus’s current state and future prospects, offering investors a chance to better understand the company’s potential and its place in the market.